secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001193125-22-151761
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Q1 2022 net loss $9.1M; cash $216.7M, runway through 2025
----------------------------------------------------------------

- Cash, cash equivalents and marketable securities totaled $216.7M as of March 31, 2022, down from $225.9M at year-end 2021; expected to fund operations through 2025.
- R&D expenses rose to $6.0M from $2.6M YoY due to ongoing Phase 1 trial (INTERCEPT-AD) of ACU193 for early Alzheimer's.
- Net loss was $9.1M vs $27.0M in Q1 2021; prior-year loss included $23.2M non-cash expense from warrant/liability fair value changes.
- Topline data from INTERCEPT-AD Phase 1 trial expected in first half of 2023; enrollment ongoing.
- Preclinical evidence supporting ACU193's selective targeting of soluble amyloid-beta oligomers published in Frontiers in Neuroscience.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522151761/0001193125-22-151761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522151761/d357212d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-151761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer